30 likes | 147 Views
Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions. Risk Ratio % 95% CI. Benefit. Harm. Statins 0.69 (0.59-0.80) n=13 (16,228/11,279) n-3 fatty acids 0.44 (0.18-1.07) n=3 (1,348/1,349) Fibrates 0.98 (0.78-1.24)
E N D
Risk Ratio for Coronary Heart Disease Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Risk Ratio % 95% CI Benefit Harm Statins 0.69 (0.59-0.80) n=13 (16,228/11,279) n-3 fatty acids 0.44 (0.18-1.07) n=3 (1,348/1,349) Fibrates 0.98 (0.78-1.24) n=12 (9,873/11,496) Resins 0.71 (0.51-0.99) n=8 (3,280/3,257 Hormones 1.04 (0.93-1.17) n=8 (4,516/9,039) Niacin acids 0.85 (0.83-1.10) n=2 (1,196/2,932) Diet 0.91 (0.82-1.01) n=16 (48,481/59,042) .1 .2 .3 .4 .5 .6 .7 .8 .9 1.0 2 Arterioscler Thromb Vasc Biol. 1999;19:187-195
Risk Ratio for Overall Mortality in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Risk Ratio % 95% CI Benefit Harm Statins 0.79 (0.71-0.89) n=13 (16,228/11,279) n-3 fatty acids 0.66 (0.53-0.88) n=3 (1,348/1,349) Fibrates 1.06 (0.78-1.48) n=12 (9,873/11,496) Resins 0.85 (0.66-1.08) n=8 (3,280/3,257 Hormones 1.09 (1.00-1.20) n=8 (4,516/9,039) Niacin acids 0.96 (0.86-1.08) n=2 (1,196/2,932) Diet 0.97 (0.81-1.15) n=16 (48,441/59,042) .4 .5 .6 .7 .8 .9 1.0 2 Arterioscler Thromb Vasc Biol. 1999;19:187-195
Risk Ratio for Mortality Other Than From CHD in 59 Randomized Controlled Trials of Cholesterol-Lowering Interventions Risk Ratio % 95% CI Benefit Harm Statins 0.97 (0.81-1.16) n=13 (16,228/11,279) n-3 fatty acids 1.16 (0.63-2.12) n=3 (1,348/1,349) Fibrates 1.16 (0.63-2.12) n=12 (9,873/11,496) Resins 1.07 (0.74-1.55) n=8 (3,280/3,257 Hormones 1.29 (1.08-1.57) n=8 (4,516/9,039) Niacin acids 0.99 (0.76-1.29) n=2 (1,196/2,932) Diet 1.00 (0.95-1.05) n=16 (48,481/59,042) .6 .7 .8 .9 1.0 2 3 Arterioscler Thromb Vasc Biol. 1999;19:187-195